Open AccessThis article is
- freely available
Epigenetic Therapy in Human Choriocarcinoma
Department of Obstetrics and Gynecology, Oita University Faculty of Medicine, Oita, Japan
Department of Obstetrics and Gynecology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879-5593, Japan
* Author to whom correspondence should be addressed.
Received: 18 August 2010; in revised form: 3 September 2010 / Accepted: 9 September 2010 / Published: 10 September 2010
Abstract: Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs) were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in choriocarcinoma cell lines. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating choriocarcinoma, with a special focus on preclinical studies.
Keywords: choriocarcinoma; epigenetics; histone deacetylase inhibitors
Citations to this Article
Cite This Article
MDPI and ACS Style
Takai, N.; Narahara, H. Epigenetic Therapy in Human Choriocarcinoma. Cancers 2010, 2, 1683-1688.
Takai N, Narahara H. Epigenetic Therapy in Human Choriocarcinoma. Cancers. 2010; 2(3):1683-1688.
Takai, Noriyuki; Narahara, Hisashi. 2010. "Epigenetic Therapy in Human Choriocarcinoma." Cancers 2, no. 3: 1683-1688.